Astellas, Pfizer agree to co-promote Caduet

More co-promotion for Astellas Pharma. The Japanese company inked a deal with Pfizer to promote the latter's combo cardiovascular drug Caduet. Pfizer will make and sell the drug, which puts the blood-pressure treatment Norvasc and cholesterol drug Lipitor in one tablet. Astellas and Pfizer will promote the drug together; Pfizer will book sales and Astellas will get a fee.

Earlier this month, Astellas made a deal with AstraZeneca to co-promote the asthma drug Symbicort. AstraZeneca is already looking for government approval of the drug in Japan; once it's OK'd for the market, Astellas will handle sales through its already established channels, and the two companies will both promote the product. 

- see the Astellas release

Related Articles:
Astellas reorganizes R&D ops
Astellas drops bid for CV Therapeutics

Suggested Articles

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.

A phase 1 study of the Inlyta-Keytruda regimen, which bears a first-line nod for kidney cancer, got the ax along with several Bavencio tests.

With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, Incyte's other JAK med Jakafi is also looking for a win in that indication.